2.25
Maravai Lifesciences Holdings Inc stock is traded at $2.25, with a volume of 3.24M.
It is down -4.39% in the last 24 hours and up +12.18% over the past month.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
See More
Previous Close:
$2.37
Open:
$2.34
24h Volume:
3.24M
Relative Volume:
1.21
Market Cap:
$323.96M
Revenue:
$288.95M
Net Income/Loss:
$-119.03M
P/E Ratio:
-2.4986
EPS:
-0.9005
Net Cash Flow:
$60.67M
1W Performance:
+2.07%
1M Performance:
+12.18%
6M Performance:
-60.04%
1Y Performance:
-74.51%
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Name
Maravai Lifesciences Holdings Inc
Sector
Industry
Phone
(858) 546-0004
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MRVI
Maravai Lifesciences Holdings Inc
|
2.25 | 330.42M | 288.95M | -119.03M | 60.67M | -0.9005 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-26-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
Dec-19-24 | Initiated | Guggenheim | Neutral |
Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
Nov-08-24 | Downgrade | William Blair | Outperform → Mkt Perform |
Aug-28-24 | Initiated | Wells Fargo | Overweight |
Aug-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-10-24 | Initiated | Craig Hallum | Buy |
Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
Aug-08-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
May-23-23 | Downgrade | Credit Suisse | Outperform → Neutral |
May-09-23 | Downgrade | Goldman | Buy → Neutral |
Jan-05-23 | Downgrade | UBS | Buy → Neutral |
Dec-14-22 | Initiated | Deutsche Bank | Buy |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Nov-03-22 | Downgrade | BofA Securities | Buy → Neutral |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Dec-16-20 | Initiated | KeyBanc Capital Markets | Overweight |
Dec-15-20 | Initiated | BofA Securities | Buy |
Dec-15-20 | Initiated | Credit Suisse | Outperform |
Dec-15-20 | Initiated | Goldman | Buy |
Dec-15-20 | Initiated | Jefferies | Buy |
Dec-15-20 | Initiated | Robert W. Baird | Outperform |
Dec-15-20 | Initiated | Stifel | Buy |
Dec-15-20 | Initiated | William Blair | Outperform |
Dec-14-20 | Initiated | UBS | Buy |
View All
Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Holdings Cut by Bank of America Corp DE - Defense World
ProShare Advisors LLC Raises Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI) - Defense World
Maravai LifeSciences Announces Shareholder Meeting Results - Investing.com India
Maravai Lifesciences Holds Annual Shareholders Meeting - TipRanks
Maravai LifeSciences Announces Shareholder Meeting Results By Investing.com - Investing.com UK
BNP Paribas Financial Markets Purchases Shares of 66,443 Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
CORRECTION -- Maravai LifeSciences Releases 2024 Sustainability Report | MRVI Stock News - GuruFocus
Maravai LifeSciences Releases 2024 Sustainability Report Highlighting Product Innovation, Governance Enhancements, and Commitment to Sustainable Growth - Nasdaq
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report - GlobeNewswire
Maravai Sustainability Report: 10x Manufacturing Expansion Plus Major Green Energy Milestones - Stock Titan
Maravai LifeSciences Releases 2024 Sustainability Report - GlobeNewswire
Maravai LifeSciences Sustainability Report: 49 New Products and 10X GMP Manufacturing Expansion Drive Growth - Stock Titan
Northern Trust Corp Buys 53,474 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Revolutionary mRNA Synthesis Kit Achieves 2X Yield, 85% Lower dsRNA: TriLink's Game-Changing Launch - Stock Titan
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Maravai LifeSciences Q1 2025 Earnings Call: Growth Amid Challenges - TipRanks
Price T Rowe Associates Inc. MD Acquires 7,946 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Robert W. Baird Has Lowered Expectations for Maravai LifeSciences (NASDAQ:MRVI) Stock Price - Defense World
Stock Traders Buy Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI) - Defense World
TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines - marketscreener.com
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q1 Loss, Tops Revenue Estimates - MSN
RBC Capital Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI) - The Globe and Mail
Major mRNA Vaccine Breakthrough: TriLink and IVI Join Forces to Transform Global Vaccine Access - Stock Titan
Maravai (MRVI) Offers 2025 Revenue Outlook Excluding Key Factors - GuruFocus
MRVI: Analyst Firm Lowers Price Target for Maravai LifeSciences - GuruFocus
These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Maravai LifeSciences (MRVI) Exceeds Q1 Revenue Expectations | MR - GuruFocus
Maravai (MRVI) Offers 2025 Revenue Outlook Excluding Key Factors | MRVI Stock News - GuruFocus
Maravai Lifesciences (MRVI) Price Target Reduced by Baird Analys - GuruFocus
Assessing Maravai LifeSciences: Insights From 5 Financial Analysts - Benzinga
Maravai LifeSciences (MRVI) Target Price Lowered by Baird | MRVI Stock News - GuruFocus
MRVI: Analyst Reduces Price Target but Maintains Buy Rating on M - GuruFocus
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2025 Earnings Call Transcript - Insider Monkey
Maravai Lifesciences (MRVI) Price Target Reduced by Baird Analyst | MRVI Stock News - GuruFocus
Maravai LifeSciences Holdings Inc (MRVI) Q1 2025 Earnings Call Highlights: Navigating Growth ... - Yahoo Finance
Maravai LifeSciences Holdings Inc (MRVI) Q1 2025 Earnings Call H - GuruFocus
Maravai LifeSciences Holdings, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:MRVI) - Seeking Alpha
Earnings call transcript: Maravai Lifesciences Q1 2025 sees revenue beat, stock up - Investing.com
Maravai LifeSciences Q1 Adjusted Loss Widens, Revenue Falls - marketscreener.com
Maravai LifeSciences Q1 2025 Earnings: Revenue Beats Estimates a - GuruFocus
Maravai LifeSciences (MRVI) Exceeds Q1 Revenue Expectations | MRVI Stock News - GuruFocus
Maravai Lifesciences Reports First Quarter 2025 Financial Results | MRVI Stock News - GuruFocus
Maravai Lifesciences Reports First Quarter 2025 Financial Results - The Manila Times
Dimensional Fund Advisors LP Grows Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Class Action Filed Against Maravai LifeSciences Holdings, Inc. (MRVI)May 5, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Maravai LifeSciences (MRVI) Expected to Announce Earnings on Monday - Defense World
Investigation announced for Long-Term Investors in shares - openPR.com
Envestnet Asset Management Inc. Lowers Stock Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai Lifesciences Holdings Inc Stock (MRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):